Literature DB >> 26861657

New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.

Romain Cohen1, Magali Svrcek2,3, Chantal Dreyer1, Pascale Cervera2,3, Alex Duval4, Marc Pocard5,6, Jean-François Fléjou2,3, Aimery de Gramont5,7, Thierry André8,9,10,11.   

Abstract

Recently, colorectal cancer (CRC) subtyping consortium identified four consensus molecular subtypes (CMS1-4). CMS1 is enriched for deficient mismatch repair (dMMR) and BRAF (V600E) tumors. Intriguingly, this subtype has better relapse-free survival but worse overall survival after relapse compared with the other subtypes. Growing evidence is accumulating on the benefit of specific therapeutic strategies such as immune checkpoint inhibition therapy in dMMR tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in tumors harboring BRAF (V600E) mutation. After reviewing dMMR prognostic value, immune checkpoints as major targets for dMMR carcinomas will be highlighted. Following, BRAF (V600E) prognostic impact will be reviewed and therapeutic strategies with the combination of cytotoxic agents and especially the combinations of BRAF and MAPK inhibitors will be discussed.

Entities:  

Keywords:  BRAF mutation; Immune checkpoint; Microsatellite instability; PD-1; PD-L1

Mesh：

Substances：

Year:  2016        PMID： 26861657     DOI： 10.1007/s11912-016-0504-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  55 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Drug combo beneficial in colorectal cancer.

Authors: 
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

4.  Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.

Authors:  Coralie Dorard; Aurélie de Thonel; Ada Collura; Laetitia Marisa; Magali Svrcek; Anaïs Lagrange; Gaetan Jego; Kristell Wanherdrick; Anne Laure Joly; Olivier Buhard; Jessica Gobbo; Virginie Penard-Lacronique; Habib Zouali; Emmanuel Tubacher; Sylvain Kirzin; Janick Selves; Gérard Milano; Marie-Christine Etienne-Grimaldi; Leila Bengrine-Lefèvre; Christophe Louvet; Christophe Tournigand; Jérémie H Lefèvre; Yann Parc; Emmanuel Tiret; Jean-François Fléjou; Marie-Pierre Gaub; Carmen Garrido; Alex Duval
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

5.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.

Authors:  R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

6.  Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.

Authors:  Sahra Bodo; Chrystelle Colas; Olivier Buhard; Ada Collura; Julie Tinat; Noémie Lavoine; Agathe Guilloux; Alexandra Chalastanis; Philippe Lafitte; Florence Coulet; Marie-Pierre Buisine; Denisa Ilencikova; Clara Ruiz-Ponte; Miriam Kinzel; Sophie Grandjouan; Hilde Brems; Sophie Lejeune; Hélène Blanché; Qing Wang; Olivier Caron; Odile Cabaret; Magali Svrcek; Dominique Vidaud; Béatrice Parfait; Alain Verloes; Ulrich J Knappe; Florent Soubrier; Isabelle Mortemousque; Alexander Leis; Jessie Auclair-Perrossier; Thierry Frébourg; Jean-François Fléjou; Natacha Entz-Werle; Julie Leclerc; David Malka; Odile Cohen-Haguenauer; Yael Goldberg; Anne-Marie Gerdes; Faten Fedhila; Michèle Mathieu-Dramard; Richard Hamelin; Badre Wafaa; Marion Gauthier-Villars; Franck Bourdeaut; Eamonn Sheridan; Hans Vasen; Laurence Brugières; Katharina Wimmer; Martine Muleris; Alex Duval
Journal:  Gastroenterology       Date:  2015-06-25       Impact factor: 22.682

7.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

Authors:  A Zaanan; P Cuilliere-Dartigues; A Guilloux; Y Parc; C Louvet; A de Gramont; E Tiret; S Dumont; B Gayet; P Validire; J-F Fléjou; A Duval; F Praz
Journal:  Ann Oncol       Date:  2009-10-15       Impact factor: 32.976

9.  Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

Authors:  Amy J French; Daniel J Sargent; Lawrence J Burgart; Nathan R Foster; Brian F Kabat; Richard Goldberg; Lois Shepherd; Harold E Windschitl; Stephen N Thibodeau
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

10.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568
View more
  9 in total

1.  Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers.

Authors:  Katerina Shulman; Ofra Barnett-Griness; Vered Friedman; Joel K Greenson; Stephen B Gruber; Flavio Lejbkowicz; Gad Rennert
Journal:  JCO Precis Oncol       Date:  2018-07-16

Review 2.  Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Authors:  David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz
Journal:  Curr Gastroenterol Rep       Date:  2019-01-30

Review 3.  Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.

Authors:  Angelika Copija; Dariusz Waniczek; Andrzej Witkoś; Katarzyna Walkiewicz; Ewa Nowakowska-Zajdel
Journal:  Int J Mol Sci       Date:  2017-01-06       Impact factor: 5.923

4.  Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation.

Authors:  Chi-Jung Huang; Shih-Hung Huang; Chih-Cheng Chien; Henry Hsin-Chung Lee; Shung-Haur Yang; Chun-Chao Chang; Chia-Long Lee
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

Review 5.  Mechanisms and Therapy for Cancer Metastasis to the Brain.

Authors:  Federica Franchino; Roberta Rudà; Riccardo Soffietti
Journal:  Front Oncol       Date:  2018-05-24       Impact factor: 6.244

6.  CT-Based Radiomics Signature: A Potential Biomarker for Predicting Postoperative Recurrence Risk in Stage II Colorectal Cancer.

Authors:  Shuxuan Fan; Xiaonan Cui; Chunli Liu; Xubin Li; Lei Zheng; Qian Song; Jin Qi; Wenjuan Ma; Zhaoxiang Ye
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

7.  Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).

Authors:  Neal J Meropol; Yang Feng; Jean L Grem; Mary F Mulcahy; Paul J Catalano; John S Kauh; Michael J Hall; Joel N Saltzman; Thomas J George; Jeffrey Zangmeister; Elena G Chiorean; Puneet S Cheema; Peter J O'Dwyer; Al B Benson
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

Review 8.  Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.

Authors:  Cong-Min Zhang; Jin-Feng Lv; Liang Gong; Lin-Yu Yu; Xiao-Ping Chen; Hong-Hao Zhou; Lan Fan
Journal:  Int J Environ Res Public Health       Date:  2016-09-08       Impact factor: 3.390

9.  Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream).

Authors:  Antonio J Ruiz-Rodríguez; Maria P Molina-Vallejo; Inés Aznar-Peralta; Cristina González Puga; Inés Cañas García; Encarna González; Jose A Lorente; M Jose Serrano; M Carmen Garrido-Navas
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.